[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-intestinal-bacterial-overgrowth\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-intestinal-bacterial-overgrowth":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,79,102,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100401388","indiana-university-gastrointestinal-motility-diagnosis-registry-100401388",false,"NCT04506593","Indiana University Gastrointestinal Motility Diagnosis Registry","Gastrointestinal Motility Diagnosis Registry","Inclusion Criteria:\n\n1. Patients who presented to the GI outpatient clinics, in-patient consult service, and outpatient endoscopy centers within the Division of Gastroenterology and Hepatology\n2. Carries a diagnosis of GI motility disorder based on the diagnostic criteria listed in table\n\nExclusion Criteria:\n\n1\\. Coexisting medical conditions that may limiting participation in clinical research trial","ALL",{"count":18,"type":19},5000,"ESTIMATED","10 Years","OBSERVATIONAL","Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders",[24,25,26,27,28,29,30,31,32],"Eosinophilic Esophagitis","Gastroesophageal Reflux Disease (GERD)","Gastroparesis","Functional Vomiting","Irritable Bowel Syndrome (IBS)","Constipation","Chronic Intestinal Pseudo-obstruction","Fecal Incontinence","Small Intestinal Bacterial Overgrowth",[34,35,36,37,38,39,40,26],"Eosinophilic esophagitis","Chronic intestinal pseudo-obstruction","Small Bowel dysmotility","SIBO","Vomiting","Functional dyspepsia","Functional bloating","RECRUITING","2026-06-15",{"date":44,"type":45},"2026-06-16","ACTUAL",{"date":47,"type":45},"2014-11-01",{"date":49,"type":19},"2026-11",{"name":51,"class":52},"Indiana University","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100513622","phase-1-pilot-feasibility-study-of-fecal-microbiota-transplant-for-the-treatment-of-small-intestinal-bacterial-overgrowth-100513622","NCT05967871","Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth","Inclusion Criteria:\n\n* Patients 3-18 years old\n* Patients will discontinue antibiotics for at least 1 week prior to FMT\n* A diagnosis of SIBO established through lactose breath test (LBT), and showing of symptoms of SIBO\n\nExclusion Criteria:\n\n* Participants will not be permitted to start any new treatments (including antibiotics, probiotics, antacid treatments, or antimotility treatments) until Week 8, unless clinically indicated\n* We will exclude participants \\\u003C3yo to avoid potential concerns of microbial transmission in young children, and to ensure participants are developmentally able to perform LBT\n\n  * All potential participants should request a referral through their primary, or subspecialty physician. We would be pleased to help facilitate this contact if needed, provided the appropriate contact information can be sent.","3 Years","18 Years",{"count":63,"type":19},20,"INTERVENTIONAL",[66],"PHASE1","The objective of the study is to assess feasibility, and clinical efficacy of a novel Fecal Microbiota Transplantation protocol for the treatment of pediatric small intestinal bacterial overgrowth (SIBO).",[32],"2025-08-15",{"date":71,"type":45},"2025-08-21",{"date":73,"type":45},"2024-03-11",{"date":75,"type":19},"2026-12-31",{"name":77,"class":52},"McMaster Children's Hospital",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":64,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":53},"100539020","phase-1-evaluating-the-effect-of-rifaximin-on-the-gut-microbiota-and-metabolome-in-sibo-using-capscan-100539020","NCT06298409","Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®","Evaluating the Effect of Rifaximin on the Regional Composition of the Gut Microbiota and Metabolic Profiles of Subjects With SIBO Using the CapScan® Collection Capsule","Inclusion Criteria:\n\n* Males or females 18 years of age or older and 80 years of age or younger at the time of the first Screening Visit.\n* ASA Classification 1 or 2.\n* For women of childbearing potential, negative urine pregnancy test within 7 days of Screening Visit.\n* Willingness to use highly effective contraception during the entire study period (e.g.: implants, injectables, oral contraceptives, intra-uterine device or declared abstinence).\n* Subject is fluent in English and understands the study protocol and informed consent and is willing and able to comply with study requirements and sign the informed consent form.\n* Positive for at least one clinical symptom consistent with SIBO.\n* Positive lactulose breath test for SIBO, by Hydrogen (H2) criteria.\n* Prescribed, but has not started, a two-week course of Rifaximin for SIBO.\n\nExclusion Criteria:\n\n* History of any of the following: Prior gastric or esophageal surgery, including lap banding or bariatric surgery, bowel obstruction, gastric outlet obstruction, diverticulitis, inflammatory bowel disease, ileostomy or colostomy, gastric or esophageal cancer, achalasia, esophageal diverticulum, active dysphagia or odynophagia.\n* Actively taking a proton-pump-inhibitor medication within 30 days of enrollment\n* Pregnancy or planned pregnancy within 30 days from Screening Visit, or breast-feeding\n* Any form of active substance abuse or dependence (including drug or alcohol abuse), unstable medical or psychiatric disorder, or any chronic condition susceptible, in the opinion of the investigator, to interfere with the conduct of the study\n* A clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the subject while involved in the study","80 Years",{"count":88,"type":19},34,[66],"We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)",[32],"2025-06-08",{"date":94,"type":45},"2025-06-11",{"date":96,"type":45},"2024-02-15",{"date":98,"type":19},"2026-02-28",{"name":100,"class":101},"Envivo Bio Inc","INDUSTRY",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":64,"phases":111,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":53},"100540484","the-safety-and-efficacy-of-a-probiotic-intervention-on-lactulose-hydrogen-breath-test-positive-patients-and-related-gastrointestinal-symptoms-100540484","NCT06317441","The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms","Inclusion Criteria:\n\n1. Aged 18-65 years old at the inclusion of the study, both female and male subjects.\n2. Signed Informed Consent; willing and able to comply with study procedures.\n3. Willing to maintain their diet and physical activity levels during the study.\n4. Able to swallow a size-00 capsule (23mm length and 9mm width).\n5. Participants with at least one of the following Rome IV diagnoses: FABD, functional diarrhea, IBS-M, or IBS-D.\n6. Baseline weekly average of worst daily (in past 24 hours) abdominal bloating\u002Fdistension score of \\>= 3.0 on a 0-to-10-point scale.\n7. Participants with abnormal LHBT following the North American Consensus recommendations (A rise in hydrogen of ≥20 ppm by 90 min).\n\nExclusion Criteria:\n\n1. History of less than three (3) bowel movements per week.\n2. With the diagnosis of IBS-C.\n3. Prior gastrointestinal disease, surgery, or abdominal or pelvic radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, any IBD, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable.\n4. Persons with central venous catheters.\n5. History of known structural gastrointestinal abnormalities such as structures or fistulas leading to mechanical obstruction.\n6. Known history abdominal radiation treatment.\n7. Use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, or GLP-1 analogues); laxative use is allowed if used less than 3 times a week and it is willing to keep unchanged in the week prior to the SIMBA capsule ingestions. Proton pump inhibitors (PPIs) are allowed provided a wash-out period of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter.\n\n   o Prokinetic use. Potential participants who are not using prokinetics to treat SIBO may be eligible after a 2-week washout period, and willing to not use prokinetics for the study duration.\n8. Unable to stop using laxatives or prokinetic medications for 4 days before the study procedure (BT). Laxatives can be resumed after the test is conducted.\n9. Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome.\n10. Celiac disease (treated or untreated).\n11. Any significant heart, liver, lung, kidney, blood, endocrine or nervous system disease, which in the opinion of the investigator, would adversely affect study safety or outcome.\n12. Cancer diagnosis or treatment within the past year (non-melanoma skin cancers are acceptable).\n13. Gastrointestinal inflammatory diseases, including ulcerative colitis, Crohn's disease, microscopic colitis.\n14. Participants with IBS presenting with alarm symptoms such as: rectal bleeding, unexplained weight loss, iron deficiency anemia, and nocturnal symptoms,\n15. Participants over the age of 50 or older who have not had:\n\n    * a colon cancer screening by either a negative FIT or FOBT test within the last 2 years; OR\n    * a colonoscopy in the prior 10 years which was negative for colorectal cancer\n16. Epilepsy diagnosis.\n17. History or diagnosis of immunological diseases, infectious diseases or immune-compromised conditions, which in the opinion of the investigator, would adversely affect study safety or outcome. Such as, but not limited to, hepatitis, tuberculosis, HIV positive, Parkinson's, multiple sclerosis, AIDS, lymphoma, and long-term corticosteroid treatment.\n18. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration.\n19. Antibiotic use (except for topical use) ≤ 12 weeks prior to screening. Potential participants may be eligible once a 12-week washout is completed.\n20. Regular use of probiotics, prebiotics or synbiotics (including food and drinks containing added probiotics and\u002For probiotic yogurts with live, active cultures) within 1 month prior to screening. Potential participants may be eligible once a 1-month washout is completed.\n21. Any prior Fecal Microbiota Transplantation.\n22. Pregnant or breastfeeding.\n23. Planning to become pregnant.\n24. Alcohol or drug abuse.\n25. Allergy to the components present in the probiotic and placebo capsules.\n26. Are non-English speaking.\n27. Are scheduled for an MRI at any time during the study. Potential participants may be eligible to participate once their MRI procedure is completed.","65 Years",{"count":110,"type":19},105,[112],"NA","The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO). Two doses of probiotic will be evaluated against placebo.",[32,37],[116,117,118,119,120,121,122,123,124,125],"Functional abdominal bloating and distension","Functional Diarrhea","Irritable Bowel Syndrome with Diarrhea","Irritable Bowel Syndrome","Abdominal Bloating","IBS","IBS-D","FABD","Functional Gastrointestinal Disorders","FGID","2025-04-24",{"date":128,"type":45},"2025-04-29",{"date":130,"type":45},"2024-07-20",{"date":132,"type":19},"2026-12",{"name":134,"class":101},"Nimble Science Ltd.",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":141,"sex":16,"minAge":61,"maxAge":108,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100553228","methane-and-hydrogen-breath-test-for-the-diagnosis-of-small-intestinal-bacterial-overgrowth-100553228","NCT06483360","Methane and Hydrogen Breath Test for the Diagnosis of Small Intestinal Bacterial Overgrowth","Inclusion Criteria:\n\nInclusion criteria for the experimental group:\n\n1. Age 18-65 years old and gender;\n2. Patients with functional gastrointestinal disease are characterized by abdominal symptoms (abdominal distension, early satiety, diarrhea, constipation, abdominal pain, etc.)\n3. have the autonomy to complete methane and hydrogen breath testing and gastrointestinal symptom scoring independently or with medical assistance;\n4. able to complete the signing of informed consent as required.\n\nInclusion criteria for the control group:\n\n1. Age 18-65 years old and gender;\n2. Healthy individuals without obvious typical gastrointestinal symptoms;\n3. Autonomy to complete methane and hydrogen breath testing and gastrointestinal symptom scoring independently or with medical assistance;\n4. Ability to complete the informed consent form as required.\n\nExclusion Criteria:\n\n1. Patients whose gastroenteroscopy within one year indicated malignant tumor of digestive tract, or whose above examination proved peptic ulcer within two months;\n2. A history of malignant tumors of the digestive system (not limited to the digestive tract), a history of inflammatory bowel disease, or a history of false or mechanical ileus;\n3. Gastrointestinal resection, appendectomy and cholecystectomy within one year;\n4. History of gastrointestinal perforation, gastrointestinal bleeding, cholangitis, acute and chronic pancreatitis within one year;\n5. There is evidence of gastrointestinal tract infection (Helicobacter pylori, acute infectious enteritis);\n6. History of type I diabetes and primary hypothyroidism;\n7. Confirmed lactose malabsorption, lactose intolerance, and pancreatic exocrine insufficiency;\n8. Within 4 weeks, a history of antibiotic administration;\n9. Within 2 weeks, history of endoscopy;\n10. Within 1 week, history of taking gastrointestinal stimulants, probiotics, laxatives;\n11. 1 day prior to testing, eating fermentable foods (yogurt, kimchi, soy sauce, tempeh, oats, beer, etc.);\n12. Not fasting 8 hours prior to testing;\n13. Smoking, strenuous exercise 2 hours before and during the test;\n14. Preparation for pregnancy, pregnancy, breastfeeding women, or overall poor compliance, or other conditions that the investigator believes need to be excluded.",true,{"count":143,"type":19},750,"To investigate whether the positive rates of methane and hydrogen breath test were different between the experimental group and the control group.",[32],[147,148,149],"Small intestinal bacterial overgrowth","Methane and hydrogen breath test","Cut-off","NOT_YET_RECRUITING","2024-08-26",{"date":153,"type":45},"2024-08-27",{"date":155,"type":19},"2024-09-01",{"date":157,"type":19},"2025-12-31",{"name":159,"class":52},"Shanghai Jiao Tong University School of Medicine"]